Stock RNAC CARTESIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
25.46 USD +3.50% Intraday chart for Cartesian Therapeutics, Inc. -4.47% +23.10%
May. 22 Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate MT
Apr. 23 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT

Evolution of the average Target Price on Cartesian Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

27487012c0da99fbfe2a96.ddd5o7NcZzU7BoRKGwYo3OaHsp55HRVht8_XtknugBc.MYQS7cQ7KwQCdM0dNlEYipDS9ehOc2Ej4ZuehzGk0m0R5jCX5zEkXktK7w~1ddb1407c94e36734cea4df637eb31c6

Analyst Recommendations on Cartesian Therapeutics, Inc.

Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
SELECTA BIOSCIENCES : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
SELECTA BIOSCIENCES : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
SELECTA BIOSCIENCES : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
25.46 USD
Average target price
56.25 USD
Spread / Average Target
+120.93%
High Price Target
90 USD
Spread / Highest target
+253.50%
Low Price Target
39 USD
Spread / Lowest Target
+53.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cartesian Therapeutics, Inc.

Leerink Partners
Mizuho Securities
Needham & Co.
HC Wainwright
Canaccord Genuity
SVB Securities LLC
BTIG
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.